NASDAQ:XNCR

Xencor Competitors

$39.59
-0.88 (-2.17 %)
(As of 04/12/2021 05:20 PM ET)
Add
Compare
Today's Range
$39.37
Now: $39.59
$41.04
50-Day Range
$40.81
MA: $45.47
$50.99
52-Week Range
$26.80
Now: $39.59
$58.35
Volume217,906 shs
Average Volume235,940 shs
Market Capitalization$2.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8

Competitors

Xencor (NASDAQ:XNCR) Vs. JAZZ, MRVI, UTHR, MRTX, BBIO, and GWPH

Should you be buying XNCR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Xencor, including Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), and GW Pharmaceuticals (GWPH).

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Xencor (NASDAQ:XNCR) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Xencor's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.23$523.37 million$14.6011.12
Xencor$156.70 million14.64$26.88 million$0.4686.07

Jazz Pharmaceuticals has higher revenue and earnings than Xencor. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Jazz Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Insider and Institutional Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Jazz Pharmaceuticals and Xencor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Xencor-113.40%-13.56%-12.03%

Analyst Ratings

This is a breakdown of current ratings and target prices for Jazz Pharmaceuticals and Xencor, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111502.82
Xencor20702.56

Jazz Pharmaceuticals currently has a consensus price target of $185.8824, suggesting a potential upside of 14.54%. Xencor has a consensus price target of $47.1111, suggesting a potential upside of 19.00%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Xencor on 12 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Xencor (NASDAQ:XNCR) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Maravai LifeSciences and Xencor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Xencor-113.40%-13.56%-12.03%

Earnings and Valuation

This table compares Maravai LifeSciences and Xencor's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Xencor$156.70 million14.64$26.88 million$0.4686.07

Xencor has higher revenue and earnings than Maravai LifeSciences.

Analyst Ratings

This is a breakdown of current ratings and target prices for Maravai LifeSciences and Xencor, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Xencor20702.56

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 8.99%. Xencor has a consensus price target of $47.1111, suggesting a potential upside of 19.00%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Maravai LifeSciences.

Summary

Maravai LifeSciences beats Xencor on 5 of the 7 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and United Therapeutics (NASDAQ:UTHR) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Xencor and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
United Therapeutics33.25%15.48%11.31%

Valuation and Earnings

This table compares Xencor and United Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million14.64$26.88 million$0.4686.07
United Therapeutics$1.45 billion6.11$-104,500,000.00($2.39)-83.09

Xencor has higher earnings, but lower revenue than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.1% of United Therapeutics shares are owned by institutional investors. 3.7% of Xencor shares are owned by company insiders. Comparatively, 10.9% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xencor and United Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
United Therapeutics00703.00

Xencor currently has a consensus price target of $47.1111, suggesting a potential upside of 19.00%. United Therapeutics has a consensus price target of $219.5714, suggesting a potential upside of 10.57%. Given Xencor's higher probable upside, research analysts plainly believe Xencor is more favorable than United Therapeutics.

Risk and Volatility

Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Summary

United Therapeutics beats Xencor on 8 of the 13 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Xencor and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
Mirati TherapeuticsN/A-60.01%-54.21%

Valuation and Earnings

This table compares Xencor and Mirati Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million14.64$26.88 million$0.4686.07
Mirati Therapeutics$3.34 million2,420.73$-213,260,000.00($5.69)-28.06

Xencor has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.9% of Mirati Therapeutics shares are owned by institutional investors. 3.7% of Xencor shares are owned by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xencor and Mirati Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
Mirati Therapeutics151002.56

Xencor currently has a consensus price target of $47.1111, suggesting a potential upside of 19.00%. Mirati Therapeutics has a consensus price target of $218.5714, suggesting a potential upside of 36.88%. Given Mirati Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mirati Therapeutics is more favorable than Xencor.

Risk and Volatility

Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Summary

Mirati Therapeutics beats Xencor on 9 of the 14 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Xencor and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
BridgeBio PharmaN/A-109.88%-48.54%

Valuation and Earnings

This table compares Xencor and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million14.64$26.88 million$0.4686.07
BridgeBio Pharma$40.56 million198.17$-260,590,000.00($2.48)-21.76

Xencor has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. 3.7% of Xencor shares are owned by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xencor and BridgeBio Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
BridgeBio Pharma01902.90

Xencor currently has a consensus price target of $47.1111, suggesting a potential upside of 19.00%. BridgeBio Pharma has a consensus price target of $72.8889, suggesting a potential upside of 35.08%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Xencor.

Risk and Volatility

Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

BridgeBio Pharma beats Xencor on 9 of the 14 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and GW Pharmaceuticals (NASDAQ:GWPH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Xencor and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Valuation and Earnings

This table compares Xencor and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million14.64$26.88 million$0.4686.07
GW Pharmaceuticals$311.33 million21.93$-9,020,000.00($0.24)-907.38

Xencor has higher earnings, but lower revenue than GW Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

81.0% of GW Pharmaceuticals shares are owned by institutional investors. 3.7% of Xencor shares are owned by company insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xencor and GW Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
GW Pharmaceuticals010402.29

Xencor currently has a consensus price target of $47.1111, suggesting a potential upside of 19.00%. GW Pharmaceuticals has a consensus price target of $204.0909, suggesting a potential downside of 6.28%. Given Xencor's stronger consensus rating and higher probable upside, research analysts plainly believe Xencor is more favorable than GW Pharmaceuticals.

Risk and Volatility

Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.


Xencor Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$162.28-0.5%$9.09 billion$2.16 billion51.19
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$34.98-0.9%$9.01 billionN/A0.00
United Therapeutics logo
UTHR
United Therapeutics
1.7$198.59-2.4%$8.85 billion$1.45 billion18.79Analyst Revision
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$159.68-6.6%$8.62 billion$3.34 million-20.74
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$53.96-1.0%$8.12 billion$40.56 million-15.82Analyst Report
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.77-0.1%$6.83 billion$311.33 million-126.61
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$123.37-1.8%$6.75 billion$14.98 million-15.03High Trading Volume
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$100.53-2.9%$6.73 billion$103.71 million-22.90
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.78-1.0%$6.45 billion$87.99 million-74.74News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$43.90-2.0%$6.30 billion$150,000.00-20.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.87-3.6%$5.97 billion$1.12 billion85.15
Allakos logo
ALLK
Allakos
1.7$104.41-0.6%$5.58 billionN/A-38.11
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$69.38-1.7%$5.51 billion$380.83 million-8.87
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.61-1.7%$5.46 billion$66.51 million17.09
Perrigo logo
PRGO
Perrigo
2.5$40.52-0.0%$5.41 billion$4.84 billion-675.22
Schrödinger logo
SDGR
Schrödinger
1.5$73.88-0.0%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.39-0.5%$5.10 billion$1.00 billion-11.73Analyst Report
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.31-2.2%$4.68 billionN/A0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68-2.6%$4.47 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77-1.9%$4.31 billionN/A-5.77Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30-0.2%$4.26 billion$204.89 million-36.63
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86-2.0%$4.12 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76-2.4%$3.91 billion$806.43 million-9.17Unusual Options Activity
LEGN
Legend Biotech
1.2$27.81-2.3%$3.76 billion$64.39 million0.00
I-Mab logo
IMAB
I-Mab
1.4$47.86-7.9%$3.72 billion$4.31 million-1.66
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.94-5.4%$3.67 billionN/A-21.35High Trading Volume
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24-1.0%$3.64 billion$117.91 million-10.60
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31-6.7%$3.44 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.3%$3.41 billion$114.62 million-7.53Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13-1.0%$3.35 billion$306.98 million-6.74
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59-0.1%$3.34 billionN/A-5.61
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43-0.2%$3.26 billion$339.08 million-11.88
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87-3.0%$3.20 billion$26.52 million-7.57
Insmed logo
INSM
Insmed
1.2$30.82-2.9%$3.18 billion$136.47 million-11.85
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62-3.8%$3.16 billionN/A-56.03
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95-0.4%$2.99 billion$421.03 million23.93Analyst Report
Analyst Revision
Alkermes logo
ALKS
Alkermes
1.4$18.78-1.3%$2.99 billion$1.17 billion-40.83Unusual Options Activity
Arvinas logo
ARVN
Arvinas
1.5$60.45-5.0%$2.95 billion$42.98 million-23.61
Organogenesis logo
ORGO
Organogenesis
1.0$22.98-0.6%$2.92 billion$260.98 million-383.00Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.17-0.9%$2.92 billion$80.43 million105.58
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.80 billion$901.90 million-22.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.79 billion$644.77 million-10.36
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.66 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.56 billion$60,000.00-9.85News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.56 billionN/A0.00
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.55 billion$120.28 million-146.36
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.54 billion$25 million-8.81
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.53 billion$2.11 million-8.65
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.43 billionN/A-22.51
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.